Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Director Lewis (JO:LEWJ) H. Titterton Jr. of Anixa Biosciences Inc (NASDAQ:ANIX) recently purchased 10,000 shares of the company’s common stock. The transaction, which occurred on July 31, 2025, involved a purchase at $3.08 per share, totaling $30,800. The purchase comes as the stock has declined over 8% in the past week, according to InvestingPro data. With analyst price targets ranging from $7 to $10, this $97M market cap company maintains a Fair overall financial health rating.
Following the purchase, Titterton directly owns 953,334 shares of Anixa Biosciences. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. The company’s strong liquidity position is reflected in its current ratio of 8.89. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with additional insights available to subscribers.
In other recent news, Anixa Biosciences has announced several key developments. The company received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic. This patent provides composition-of-matter protection for Anixa’s immunogenic approach to breast cancer prevention and treatment in Canada, enhancing its international intellectual property portfolio. Additionally, Anixa will soon receive a new U.S. patent covering aspects of its breast cancer vaccine technology, specifically related to methods of immunizing patients using an immunogenic composition containing human α-lactalbumin protein.
In another development, Anixa is set to obtain a U.S. patent for its ovarian cancer vaccine technology, focusing on methods targeting the anti-Müllerian hormone receptor, type II (AMHR2). Furthermore, the company has dosed the first patient in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy aimed at treating recurrent ovarian cancer. This cohort will receive a significantly higher dosage compared to previous groups, as no dose-limiting toxicities were observed in the third cohort. These advancements highlight Anixa Biosciences’ ongoing efforts in cancer vaccine and therapy development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.